Ankur Kalra, MBBS, FACC

Ankur Kalra

Professional Bio:

Dr. Ankur Kalra is a structural heart interventional cardiologist at Harrington Heart & Vascular Institute at University Hospitals Cleveland Medical Center, and Assistant Professor of Medicine (Cardiology) at Case Western Reserve University School of Medicine (Cleveland, OH). Educated at Indira Gandhi Medical College (Shimla, India), Dr. Kalra completed medical and cardiology training at the All India Institute of Medical Sciences (New Delhi, India), Cooper University Hospital (Camden, NJ), and Hennepin County Medical Center and Minneapolis Heart Institute (Minneapolis, MN). He served as a clinical and research fellow in interventional cardiology at Beth Israel Deaconess Medical Center (Boston, MA), and a clinical fellow in medicine at Harvard Medical School (Boston, MA) in 2015-16. He then completed a year of advanced interventional and structural cardiology fellowship in 2016-17, at Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital (Houston, TX), a primary academic affiliate of Weill Cornell Medical College of Cornell University and New York-Presbyterian Hospital (New York, NY). Dr. Kalra is board-certified in Internal Medicine (2012), Cardiovascular Disease (2015) and Interventional Cardiology (2016) from the American Board of Internal Medicine, and a Diplomate in Adult Comprehensive Echocardiography (2014) from the National Board of Echocardiography. He is also certified in patient safety, healthcare quality, health informatics and leadership from Harvard Medical School’s 1-year SQIL (Safety, Quality, Informatics and Leadership) certification program. His research interests include cardiovascular care quality improvement in low- and middle-income countries. Dr. Kalra is director of Barry J. Maron Hypertrophic Cardiomyopathy Center in New Delhi, India. He has presented over 45 abstracts at national and international meetings, and published over 70 manuscripts in various peer-reviewed journals.

General Statement of Disclosure:

NOTHING TO DISCLOSE

View Full Disclosure